These transactions were part of a routine process involving automatic sales to cover tax obligations related to restricted stock units. After these transactions, Devers holds 15,937 shares of Ionis common stock. Additionally, Devers was granted 33,000 restricted stock units and 22,000 performance restricted stock units, which may vest in the future based on specific performance criteria. According to InvestingPro data, analysts maintain a bullish outlook on the stock with a consensus recommendation of 1.84 (Strong Buy), and the company maintains a "Fair" overall financial health score. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro offers detailed research reports covering over 1,400 US stocks, including IONS. According to InvestingPro data, analysts maintain a bullish outlook on the stock with a consensus recommendation of 1.84 (Strong Buy), and the company maintains a "Fair" overall financial health score. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro offers detailed research reports covering over 1,400 US stocks, including IONS.
These transactions were part of a routine process involving automatic sales to cover tax obligations related to restricted stock units. After these transactions, Devers holds 15,937 shares of Ionis common stock. Additionally, Devers was granted 33,000 restricted stock units and 22,000 performance restricted stock units, which may vest in the future based on specific performance criteria.
In other recent news, Ionis Pharmaceuticals (NASDAQ:IONS) has maintained its positive standing with Piper Sandler and Needham, following the FDA’s approval of olezarsen (TRYNGOLZA) for adults with familial chylomicronemia syndrome (FCS). This approval marks Ionis Pharmaceuticals’ first solo commercial drug launch, with the drug priced at $595,000 per year, in line with expectations for treatments targeting ultra-rare diseases. The company plans to transition patients from Open-Label Extension (OLE) and Expanded Access Program (EAP) to the commercial drug during the first half of 2025. Piper Sandler projects $37 million in U.S. FCS revenue for fiscal year 2025, while Needham maintains a Buy rating for Ionis.
Additionally, Ionis Pharmaceuticals recently reported its third-quarter financial results for 2024, emphasizing non-GAAP financials, indicating confidence in their operational management and long-term prospects. The company’s revenue forecast for TRYNGOLZA in 2025 stands at $27 million, slightly under the current consensus estimate of $28 million. However, this could change with the anticipated future approval for the Severe Hypertriglyceridemia indication.
Finally, Ionis is anticipating positive results from pivotal studies for the severe hypertriglyceridemia (sHTG) indication in the second half of 2025. Analysts from Needham and TD Cowen have expressed confidence in the company’s market position and the potential of TRYNGOLZA. These recent developments underscore Ionis Pharmaceuticals’ progress and potential in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.